HeimLSTA • NASDAQ
add
Lisata Therapeutics Inc
Við síðustu lokun
2,84 $
Dagbil
2,86 $ - 2,88 $
Árabil
2,05 $ - 3,83 $
Markaðsvirði
24,35 m. USD
Meðalmagn
15,91 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 5,34 m. | -10,53% |
Nettótekjur | -4,93 m. | 6,29% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -0,59 | 9,23% |
EBITDA | -5,29 m. | 10,53% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 35,86 m. | -34,08% |
Heildareignir | 38,20 m. | -34,24% |
Heildarskuldir | 4,76 m. | -11,55% |
Eigið fé alls | 33,44 m. | — |
Útistandandi hlutabréf | 8,39 m. | — |
Eiginfjárgengi | 0,70 | — |
Arðsemi eigna | -33,03% | — |
Ávöxtun eigin fjár | -37,14% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -4,93 m. | 6,29% |
Handbært fé frá rekstri | -2,52 m. | 29,72% |
Reiðufé frá fjárfestingum | -6,30 m. | -151,46% |
Reiðufé frá fjármögnun | 0,00 | 100,00% |
Breyting á handbæru fé | -8,78 m. | -200,53% |
Frjálst peningaflæði | -857,00 þ. | 47,89% |
Um
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.
In April 2024 the FDA granted their product, certepetide, orphan drug status. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Stofnsett
1980
Höfuðstöðvar
Vefsvæði
Starfsfólk
25